At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 210 enrolled
Drug / intervention
etanercept +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
In Brief
A Phase 4 clinical trial evaluating etanercept, Placebo, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 210 participants across 47 sites in 2 countries.
Detailed Summary
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionFeb 2013
Study CompletionMay 2013
TodayJul 2026
First PostedMar 11, 2011
Enrollment StartMar 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.3 years ago
Interventions
etanerceptdrug
Administered by subcutaneous injection once weekly.
Placebodrug
Placebo subcutaneous injection
DMARD Therapydrug
Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine